In a clinical study, we observed here that a patient with NSCLC carrying an EGFR mutation and exhibiting high plasma heregulin expression achieved a response with afatinib treatment, despite having previously developed erlotinib resistance. Here, EGFR is linked to non-small cell lung carcinoma.